PBP World Meeting

Roquette’s Health & Pharma Solutions Business Unit is pleased to participate in the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting) — one of the leading global scientific conferences for formulation scientists, technologists, and R&D leaders.

Join us in Prague to explore how excipient expertise, advanced material science, and integrated digital and formulation capabilities come together to solve today’s toughest drug-delivery challenges.

At PBP 2026, we will showcase how Roquette, with the recent acquisitions of Qualicaps and IFF Pharma Solutions, is enabling pharmaceutical innovators to move from formulation concept to robust, patient-centric drug products.

Our presence will focus on our integrated Health and Pharma Solutions (HPS) portfolio, highlighting:

• Controlled and modified-release expertise
• Low nitrite excipients supporting nitrosamine risk mitigation
• ·Solubility enhancement strategies for complex molecules
• Productivity-driven formulation solutions
• The digital evolution of pharmaceutical development from lab data generation to end‑to‑end utilization

Featured Scientific Contributions

Roquette experts will deliver presentations and present multiple scientific posters, reinforcing our commitment to innovation and technical leadership.

Oral Presentation

Tuesday, 24 March 2026 | 3:00–3:40 pm | Forum Hall

Nicolas Descamps, PhD
Global Technology Liaison Manager
Topic: Digital evolution in pharma developments: our journey from traditional methods to end‑to‑end lab data automation, management and utilization

This session will highlight how digital tools and connected data ecosystems can accelerate formulation development, improve decision‑making, and enhance reproducibility across pharmaceutical R&D.

Poster Presentations (with full topics and authors)

1. Integrated In Vitro and In Vivo Characterization of Alginate-Based Anti-Reflux Formulations

Author: Matthias Knarr, PhD, Lead Scientist
A combined in vitro and MRI-based in vivo study linking alginate chemical structure to raft formation, strength, and gastric persistence

2. Developing Multiple Strengths of Controlled Release (CR) Tablet Formulations

Author: Nasim Heshmati, PhD, Application Scientist
Developing multiple strength of phenylephrine CR tablets using the direct compression method

3. Strategic Formulation of Sustained Release Matrix Tablets Using METHOCEL™, POLYOX™, and Alginate

Author: Shiyi Zhou, Pharmaceutical Technologist
Comparative evaluation of polymer functionality across APIs with varied solubility to guide sustained‑release design

4. Impact of Internal and External Lubrication on Controlled Release (CR) Tablet Properties Using PEARLITOL® CR-H

Author: Fabiana Ferraro, PhD, Application Scientist
Evaluation of tabletability, ejection force, and dissolution behavior to optimize robust direct‑compression CR matrices

5. Tuning Controlled Release (CR) Performance Through Excipient Ratio Design in PEARLITOL® CR‑H Systems

Author: Fabiana Ferraro, PhD, Application Scientist
How adjusting HPMC:mannitol ratios in co‑processed systems enables customizable CR kinetics across multiple APIs

Key Product Platforms on Display

Visitors to Booth 24 can discover Roquette’s proven and innovative excipient solutions spanning multiple formulation needs.

• Our low nitrite portfolio, designed to support proactive nitrosamine mitigation strategies, includes PEARLITOL® 200 GT mannitol, Avicel® LN low‑nitrite microcrystalline cellulose, LYCATAB® CT low‑nitrite partially pregelatinized starch, and low nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC).
• For controlled and modified-release applications, Roquette will highlight METHOCEL™ HPMC for matrix systems, POLYOX™ polyethylene oxide (PEO) for robust extended-release performance, ETHOCEL™ ethylcellulose for diffusion‑controlled release, and the PEARLITOL® portfolio mannitol‑based excipients supporting functional release design and tablet robustness.
• In the area of solubility enhancement, visitors can explore KLEPTOSE® Crysmeb methyl‑β‑cyclodextrin for complexation‑based bioavailability improvement, as well as AFFINISOL™ hydroxypropyl methylcellulose acetate succinate (HME), designed for hot‑melt extrusion and amorphous solid dispersion technologies.
• Roquette will also showcase productivity and performance‑driven excipients including Avicel® silicified microcrystalline cellulose (SMCC) and PEARLITOL® 200 GT mannitol, supporting improved flowability, compressibility, and process efficiency across oral solid dosage forms.
• For streamlined coating operations, ReadiLYCOAT®, a ready‑to‑use film coating system, will be featured as a solution to simplify coating processes while ensuring consistent performance and quality.

Innovation Spotlight: CustomCare excipients range for 3D-printed pharmaceuticals

Roquette’s new CustomCare portfolio empowers the development of 3D-printed oral dosage forms through a range of plant‑based excipients for additive manufacturing technologies including semi‑solid extrusion (SSE), fused deposition modeling (FDM), and binder jetting.

Designed for targeted functionality, on‑demand precision, and patient‑focused design, our CustomCare excipients enable the creation of personalized medicines with consistent printability, performance, and palatability. Proven in clinical settings, the portfolio supports applications ranging from pediatric and geriatric medicines to population‑specific and point‑of‑care therapies.

Roquette CustomCare solutions include:

• PEARLITOL® 50 C (mannitol) to improve drying, flow, and disintegration
• ·LYCASIN® 80/55 (maltitol syrup) for texture control and taste masking
• LYCATAB® PGS (partially pregelatinized starch) for structural integrity and chewability
• GLUCIDEX® IT 19 (maltodextrin) as a matrix base for immediate‑release formats
• KLEPTOSE® HPβCD (hydroxypropyl‑β‑cyclodextrin) to enhance solubility and print stability in fast‑dissolving systems

This technology has been demonstrated in clinical use cases such as 3D‑printed pediatric SMX/TMP chewable tablets, delivering improved palatability, bioequivalent dissolution behavior, printable ink stability, and robust process control.

At PBP 2026, Roquette will showcase how our CustomCare supported by our Technical Services & Development (TS&D) expertise in formulation screening, rheology, and printability testing, enables the translation of 3D printing from experimental concepts to patient‑ready pharmaceutical solutions.

Meet Our Experts at Booth 24

Our multidisciplinary team from Technical Service & Development, R&D, Marketing, and Scientific Affairs will be available for in‑depth discussions throughout the event. Stop by booth 24 to discuss your formulation challenges, explore scientific data and technical literature, and learn how Roquette’s integrated HPS portfolio supports oral solid dosage (OSD) development — from granulation to coating.

Learn more about the conference at 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

Stay connected with us on LinkedIn.